1. New MI, White PC. Genetic disorders of steroid metabolism. In: Thakker RV, ed. Genetic and molecular biological aspects of endocrine disease. London: Bailliere Tindall; 1995:525-54.
2. New M, Lorenzen F, Lerner A, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57(2): 320-6.
3. Temeck JW, Pang SY, Nelson C, New MI. Genetic defects of steroidogenesis in premature pubarche. J Clin Endocrinol Metab 1987;64(3):609-17.
4. Wilkins L. Adrenal disorders. II. Congenital virilizing adrenal hyperplasia. Arch Dis Child 1962;37:231.
5. Prader A. Die Haufigkeit der kongenitalen adrenogenitalen syndromes. Helv Paediatr Acta 1958;13:5-14.
6. New M, Carlson A, Obeid J, et al. Extensive Personal Experience: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001;86(12):5651-7.
7. Di Martino-Nardi J, Stoner E, O'Connell A, New MI. The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl 1986;279:305-14.
8. Premawardhana L, Hughes I, Read G, Scanlon M. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997;46(3):327-32.
9. Hargitai G, Solyom J, Battelino T, et al. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res 2001;55(4): p161-71.
10. Cabrera M, Vogiatzi M, New M. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86(7):3070-80.
11. New MI, Gertner JM, Speiser PW, del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn 1988;30:79-88.
12. Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987;47:664-70.
13. Moore G, Lacroix A, Rabin D, McKenna T. Gonadal dysfunction in adult men with congenital adrenal hyperplasia. Acta Endocrinol (Copenh 1980;95(2): p185-93.
14. Stikkelbroeck N, Otten B, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86(12): p5721-8.
15. Jones H, Verkauf B. Congenital adrenal hyperplasia: age at menarche and related events at puberty. Am J Obstet Gynecol 1971;109:292.
16. Klingensmith G, Garcia S, Jones H, Migeon C, Blizzard R. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977;90(6): p996-1004.
17. Klingensmith G, Wentz A, Meyer W, Migeon C. Gonadotropin output in congenital adrenal hyperplasia. J Clin Endorinol Metab 1976;43:933.
18. Helleday J, Siwers B, Ritzen EM, Carlstrom K. Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency. J Clin Endocrinol Metab 1993;76(4):933-6.
19. Ghali I, David M, David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1977;6(6): p425-36.
20. Richards G, Grumbach M, Kaplan S, Conte F. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978;47(6): p1208-15.
21. Granoff A. Treatment of menstrual irregularities with dexamethasone in congenital adrenal hyperplasia. J Adolesc Health Care 1981;2(1): p23-7.
22. Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. NEJM 1987;316:178-82.
23. Holmes-Walker D, Conway G, Honour J, Rumsby G, Jacobs H. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf 1995;43(3): p291-6.
24. Riddick D, Hammond C. Adrenal virilism due to 21-hydroxylase deficiency in the postmenarchial female. Obstet Gynecol 1975;45(1): p21-4.
25. Lo J, Schwitzgebel V, Tyrrell J, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999;84(3): p930-6.
26. Urban M, Lee P, Migeon C. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. New Engl J Med 1978;299:1392.
27. Valentino R, Savastano S, Tommaselli A, et al. Success of glucocorticoid replacement therapy on fertility in two adult males with 21-CAH homozygote classic form. J Endocrinol Invest 1997;20(11):690-4.
28. Molitor J, Chertow B, Fariss B. Long-term follow-up of a patient with congenital adrenal hyperplasia and failure of testicular development. Fertil Steril 1973;24:319.
29. Blumberg-Tick J, Boudou P, Nahoul K, Schaison G. Testicular tumors in congenital adrenal hyperplasia: steroid measurements from adrenal and spermatic veins. J Clin Endocrinol Metab 1991;73(5): p1129-33.
30. Cutfield R, Bateman J, Odell W. Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency). Fertil Steril 1983;40(6): p809-14.
31. Rutgers J, Young R, Scully R. The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988;12(7): p503-13.
32. Combes-Moukhovsky M, Kottler M, Valensi P, Boudou P, Sibony M, Attali J. Gonadal and adrenal catheterization during adrenal suppression and gonadal stimulation in a patient with bilateral testicular tumors and congenital adrenal hyperplasia. J Clin Endocrinol Metab 1994;79(5): p1390-4.
33. Radfar N, Bartter F, Easley R, Kolins J, Javadpour N, Sherins R. Evidence for endogenous LH suppression in a man with bilateral testicular tumors and congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977;45(6): p1194-204.
34. Kowarski A, Finkelstein J, Spaulding J, Holman G, Migeon C. Aldosterone secretion rate in congenital adrenal hyperplasia. A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. J Clin Invest 1965;44:1505.
35. Kuhnle U, Land M, Ulick S. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1986;62(5):p934-40.
36. Rose L, Newmark S, Strauss J, Pochi P. Adrenocortical hydroxylase deficiencies in acne vulgaris. J Invest Dermatol 1976;66(5): p324-6.
37. Lucky A, Rosenfield R, McGuire J, Rudy S, Helke J. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986;62(5): p840-8.
38. Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988;81(6):866-74.
39. Balsamo A, Cacciari E, Piazzi S, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996;98(3 Pt 1): p362-7.
40. Therrell BJ, Berenbaum S, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101(4 Pt 1): p583-90.
41. Cartigny-Maciejewski M, Guilley N, Vanderbecken S, et al. [Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980-1996]. Arch Pediatr 1999;6(2): p151-8.
42. Tajima T, Fujieda K, Nakae J, et al. Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan. J Clin Endocrinol Metab 1997;82(7): p2350-6.
43. Cutfield W, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995;126(1): p118-21.
44. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985;37(4):650-67.
45. Sherman SL, Aston CE, Morton NE, Speiser P, New MI. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am J Hum Genet 1988;42:830-8.
46. Nebert DW, Nelson DR, Coon MJ. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991;10:1-14.
47. Dupont B, Oberfield SE, Smithwick EM, Lee TD, Levine LS. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 1977;2(8052-8053):1309-12.
48. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci U S A 1985;82(4):1089-93.
49. Carroll MC, Campbell RD, Porter RR. The mapping of 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA 1985;82:521-5.
50. Belt KT, Carroll MC, Porter RR. The structural basis of the multiple forms of human complement component C4. Cell 1984;36(4):907-14.
51. White PC, New MI, Dupont B. Structure of the human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 1986;83(14):5111-5.
52. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci U S A 1986;83(9): p2841-5.
53. Krawczak M, Cooper DN. The human gene mutation database. Trends Genet 2003;13:121-2.
54. Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80(8):2322-9.
55. Krone N, Braun A, Roscher A, Knorr D, Schwarz H. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 2000;85(3): p1059-65.
56. Wedell A, Ritzen EM, Haglund SB, Luthman H. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acd Sci USA 1992;89(15):7232-6.
57. Morel Y, Murena M, Nicolino M, Carel JC, David M, Forest MG. Correlation between genetic lesions of the CYP21B gene and the clinical forms of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: Report of a large study of 355 CAH chromosomes. Hormone Res 1992;37:13.
58. New M. Unpublished data of 450 genotypes.
59. New M, Carlson A, Obeid J, et al. Update: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. In: New M, ed. Hormonal and Genetic Basis of Sexual Differentiation Disorders: The Endocrinologist; 2002 (supp).
60. New MI, Gertner JM, Speiser PW, del Balzo P. Final height in classical and nonclassical 21-hydroxylase deficiency adrenal hyperplasia. In: Bierich JR, Cacciari E, Raiti S, eds. Growth abnormalities. New York: Raven Press; 1989:51-61.
61. Quintos J, Vogiatzi M, Harbison M, New M. Growth Hormone Therapy Alone or in Combination with Gonadotropin-Releasing Hormone Analog Therapy to Improve the Height Deficit in Children with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2001;86(4): p1511-7.
62. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005;90(6):3318-25.
63. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endo Metab 1996;81:3535-9.
64. Merke D, Keil M, Jones J, Fields J, Hill S, Cutler G. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85(3): p1114-20.
65. Merke D, Cutler G. New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30(1): p121-35.
66. Gunther D, Bukowski T, Ritzen E, Wedell A, Van WJ. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997;82(10): p3324-7.
67. Nasir J, Royston C, Walton C, White M. 11 beta-hydroxylase deficiency: management of a difficult case by laparoscopic bilateral adrenalectomy. Clin Endocrinol (Oxf 1996;45(2): p225-8.
68. Zachmann M, Manella B, Kempken B, Knorr-Muerset G, Atares M, Prader A. Ovarian steroidogenesis in an adrenalectomized girl with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1984;21(5):575-82.
69. Gmyrek G, New M, Sosa R, Poppas D. Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics 2002;109(2): pE28.
70. Gotoh H, Kusakabe M, Shiroishi T, Moriwaki K. Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of congenital adrenal hyperplasia in humans. Endocrinology 1994;135(4): p1470-6.
71. Tajima T, Okada T, Ma X, Ramsey W, Bornstein S, Aguilera G. Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochromeP450 21-hydroxylase into the adrenal gland of21-hydroxylase-deficient mice. Gene Ther 1999;6(11): p1898-903.
72. Macapagal M, Slowinska B, Nimkarn S, et al. Gene therapy of 21-hydroxylase deficient mice utilizing an adeno-associated virus vector. In: The Endocrine Society's 84th Annual Meetign; 2002; San Francisco; 2002. p. P1-503.
73. Speiser PW, Laforgia N, Kato K, et al. First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency). J Clin Endocrinol Metab 1990;70(4):838-48.
74. Josso N. Anatomy and endocrinology of fetal sex differentiation. In: DeGroot L, Jameson J, eds. Endocrinology. 4th Edition ed. Philadelphia: W.B. Saunders Company; 2001:1947-54.
75. Wilson RC, Wei JQ, Cheng KC, Mercado AB, New MI. Rapid DNA analysis by allele-specific PCR for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab 1995;80(5):1635-40.
76. White PC, New MI. Molecular genetics of congenital adrenal hyperplasia. Baillieres Clin Endocrinol Metab 1988;2(4):941-65.
77. Forest M, Betuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res 1989;15(1-2): p277-301.
78. Lajic S, Wedell A, Bui T, Ritzen E, Holst M. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998;83(11):3872-80.
79. Seckl JR, Miller WL. How safe is long-term prenatal glucocorticoid treatment? Jama 1997;277(13):1077-9.
80. New M, Carlson A, Obeid J, et al. Update: Prenatal diagnosis for congenital adrenal hyperplasia in 595 pregnancies. The Endocrinologist 2003;13(3):233-9.
81. Carlson AD, Obeid JS, Kanellopoulou N, Wilson RC, New MI. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. In: New MI, ed. Diagnosis and Treatment of the Unborn Child. Reddick, FL: Idelson-Gnocchi Ltd. Publisher; 1999:75-84.
82. Mercado AB, Wilson RC, Cheng KC, Wei JQ, New MI. Extensive personal experience: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014-20.
83. Forest MG, David M, Morel Y. Prenatal diagnosis and treatment of 21-hydroxylase deficiency. [Review]. J Steroid Biochem Molec Biol 1993;45(1-3):75-82.
84. Barker DJP, Byll AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ 1990;301:259-62.
85. Whincup PH, Cook D, Papacosta O, Walker M. Birth weight and blood pressure: cross-sectional and longitudinal relations in childhood. BJM 1995;311:773-6.
86. Barker D, Osmond C, Simmonds S, Wield G. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993;306(6875): p422-6.
87. Barker D. Fetal origins of coronary heart disease. BMJ 1995;311(6998): p171-4.
88. Barker DJP, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938-41.
89. Barker D, Osmond C, Pannett B. Why Londoners have low death rates from ischaemic heart disease and stroke. BMJ 1992;305(6868): p1551-4.
90. Seckl J, Miller W. How safe is long-term prenatal glucocorticoid treatment? [see comments]. JAMA 1997;277(13): p1077-9.
91. Trautman PD, Meyer-Bahlburg HF, Postelnek J, New MI. Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. Psychoneuroendocrinology 1995;20(4):439-49.
92. Meyer-Bahlburg H, Dolezal C, Baker S, Carlson A, Obeid J, New M. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004;89(2): p610-4.
93. Pasterski VL, Geffner ME, Brain C, Hindmarsh P, Brook C, Hines M. Prenatal hormones and postnatal socialization by parents as determinants of male-typical toy play in girls with congenital adrenal hyperplasia. Child Dev 2005;76(1):264-78.
94. Hines M, Brook C, Conway GS. Androgen and psychosexual development: core gender identity, sexual orientation and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH). J Sex Res 2004;41(1):75-81.
95. Meyer-Bahlburg H, Dolezal C, Baker S, Carlson A, Obeid J, New M. Prenatal Androgenization Affects Gender-Related Behavior But Not Gender Identity in 5 -12-Year-Old Girls With Congenital Adrenal Hyperplasia. Arch Sex Behav 2004;33(2):97-104.
96. Meyer-Bahlburg H, Dolezal C, Baker S, Ehrhardt A, New M. Gender development in women with congenital adrenal hyperplasia (CAH) as a function of CAH subtype. Unpublished manuscript 2005.
97. Long DN, Wisniewski AB, Migeon CJ. Gender role across development in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2004;17(10):1367-73.
98. Nass R, Baker S, Speiser P, et al. Hormones and handedness: left-hand bias in female congenital adrenal hyperplasia patients. Neurology 1987;37(4):711-5.
99. Nass R, Baker S. Androgen effects on cognition: Congenital adrenal hyperplasia. Psychoneuroendo 1991;16:189-201.
100. Berenbaum SA, Korman Bryk K, Duck SC, Resnick SM. Psychological adjustment in children and adults with congenital adrenal hyperplasia. J Pediatr 2004;144(6):741-6.
101. Wisniewski AB, Migeon CJ, Malouf MA, Gearhart JP. Psychosexual outcome in women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Urol 2004;171(6 Pt 1):2497-501.
102. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. J Pediatr Adolesc Gynecol 2003;16(5):289-96.
103. Zucker KJ, Bradley SJ, Oliver G, Blake J, Fleming S, Hood J. Self-reported sexual arousability in women with congenital adrenal hyperplasia. J Sex Marital Ther 2004;30(5):343-55.